Ablynx and Taisho to develop and commercialise anti-TNFa nanobody in Japan

Belgium-based biopharmaceutical company Ablynx has entered a licence agreement with Taisho Pharmaceutical to develop and commercialise its anti-TNFa nanobody, ozoralizumab, to treat rheumatoid arthritis (RA) in Japan.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news